Click here to learn how we are responding.
Pfizer has partnered with Centogene to offer genetic testing and with GeneMatters to offer genetic counseling to individuals with or at risk of developing transthyretin amyloid cardiomyopathy (ATTR-CM). All services are anonymous and sponsored by Pfizer with no cost to eligible individuals. This program is intended to increase access to genetic testing and counseling services in order to support and empower individuals.
ATTR-CM is a life-threatening, under-recognized and under-diagnosed condition. While wild-type disease is thought to be idiopathic, hereditary ATTR-CM occurs due to a mutation in the TTR gene. TTR gene sequencing is therefore recommended for all individuals with a confirmed diagnosis of ATTR-CM to distinguish between hereditary and wild-type disease.1,2 A confirmation of hereditary ATTR-CM can help inform individuals and their family members about their risk of having or developing the disease. For those who carry a TTR gene mutation, regular follow-up with a healthcare professional is important to monitor any potential onset of disease and ensure early diagnosis.3
Have a confirmed diagnosis of ATTR-CM
Have a confirmed family history of hereditary
Are suspected to have or potentially develop ATTR-CM
To order genetic testing:
The CentoCard® is a dried blood spot card for patient sample collection and shipment. Instructions for use are provided along with the cards.
Use the CentoCard® provided by your Pfizer representative*
*If you do not already have a CentoCard®, please contact your Pfizer representative or visit CentoPortal® to register and request a CentoCard®.
Sign up for or log in to CentoPortal®
On the patient screening tab, enter the unique CentoCard® number
Select TTR single panel, enter patient details, and sign the consent form online
Collect the sample on the CentoCard®, allow the sample to dry and then place in the return envelope provided for shipment collection
Centogene is an independent, College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA) and ISO 15189 accredited laboratory. Eligible individuals must be 18 years or older and reside in the United States or Puerto Rico. Pfizer provides financial support for this program; however, all genetic testing and counseling services are provided by independent third parties. Pfizer receives no identifying patient or physician information. Physicians who use this program have no obligation to prescribe any Pfizer products. References: 1. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-1377. 2. Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin cardiac amyloidosis in older Americans. J Card Fail. 2016;22(12):996-1003. 3. Conceição I, Coelho T, Rapezzi C, et al. Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression. Amyloid. 2019;26(3):103-111.